— Know what they know.
Not Investment Advice

MLAB NASDAQ

Mesa Laboratories, Inc.
1W: +3.3% 1M: -2.8% 3M: +29.7% YTD: +63.0% 1Y: +63.6% 3Y: +35.8% 5Y: -57.4%
$129.25
-0.62 (-0.48%)
 
Weekly Expected Move ±6.2%
$113 $121 $129 $137 $145
NASDAQ · Healthcare · Medical - Specialties · Tech Score Neutral · Power 57 · $723.3M mcap · 5M float · 2.99% daily turnover · Short 63% of daily vol
Credit Risk of going bust: lower than 51% of companies Debt: 12.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $2.00 (down 98%), Mesa Laboratories, Inc. would be worth roughly what it owes.
Total debt $101.4M against a stock market value of $723.3M.
Distance to default 5.25 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $52.2M (short-term plus half of long-term), stock volatility 53.3%; Altman Z'' 0.55. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Bullish 75
Insider+$0.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$723.3M
52W Range69.51-144.35
Volume90,091
Avg Volume147,848
Beta1.05
Dividend$0.64
Analyst Ratings
3 Buy 5 Hold 0 Sell
Consensus Hold
Company Info
CEOSiddhartha C. Kadia
Employees717
SectorHealthcare
IndustryMedical - Specialties
IPO Date1984-02-29
12100 West Sixth Avenue
Lakewood, CO 80228
US
303 987 8000
About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Recent Insider Trades

NameTypeSharesPriceDate
Capone Mark Christop A-Award 2,423 — 2026-09-09
Ladiwala Shiraz Shab A-Award 2,510 — 2026-09-09
Hall Shannon A-Award 1,774 — 2026-09-09
Sullivan John James A-Award 1,774 — 2026-09-09
Tripeny R Tony A-Award 1,774 — 2026-09-09

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms